One possible treatment strategy for EVI1high leukemias with non-mutated TP53 could therefore be the use of an MDM2 inhibitor, for example, RG7388, to increase p53 protein levels and sensitize cells to subsequent therapy. Here, TP53 is linked to leukemia.